Selskabsmeddelelse03.12.2025, 18.55Lipigon Pharmaceuticals presents top-line data from the Phase II clinical trial of Lipisense in patients with elevated blood lipid levels
Pressemeddelelse14.10.2025, 22.58Lipigon Pharmaceuticals reports last patient visit in the three-month follow-up of its Phase II clinical study with Lipisense
Selskabsmeddelelse06.07.2025, 09.03Lipigon Pharmaceuticals Enrolls Last Patient in Phase II Study with Lipisense®
Pressemeddelelse27.05.2025, 08.36Redeye: Lipigon Q1 2025 - 64.5% Subscription Rate in the Rights Issue
Selskabsmeddelelse20.03.2025, 12.15Lipigon Pharmaceuticals' commercial partner announces positive results from Phase I clinical trial with Lipisense
Selskabsmeddelelse21.11.2024, 10.00Första patienten doserad i Lipigon Pharmaceuticals kliniska fas II-studie med Lipisense®
Pressemeddelelse18.09.2024, 12.51Lipigon's development partner Leaderna Therapeutics reports last person treated in ongoing Phase 1 study with Lipisense®
Selskabsmeddelelse09.07.2024, 14.00Lipigon Receives Milestone Payment of USD 1 Million from Leaderna for Approval of Phase I Bridging Study
Pressemeddelelse20.06.2024, 08.30New Publication: The ANGPTL4 Protein May Reduce the Risk of Cardiovascular Disease and Diabetes
Pressemeddelelse15.05.2024, 08.28Lipigon and Leaderna Collaboration on Lipisense® Shows Good Progress
Selskabsmeddelelse14.05.2024, 07.53Lipigon collaborates with University of Washington on lung damage project
Pressemeddelelse07.02.2024, 16.00The Swedish Medical Products Agency approves Lipigon's phase II study with Lipisense®